Genelux (NASDAQ:GNLX – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09), Zacks reports.
Genelux Stock Performance
Shares of GNLX opened at $3.08 on Friday. The firm’s 50 day moving average price is $4.06 and its two-hundred day moving average price is $3.10. Genelux has a twelve month low of $1.60 and a twelve month high of $6.50. The firm has a market cap of $106.38 million, a P/E ratio of -3.24 and a beta of -1.41.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Genelux in a report on Tuesday, March 25th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Genelux presently has an average rating of “Buy” and a consensus price target of $18.25.
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
- Five stocks we like better than Genelux
- How to Start Investing in Real Estate
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- Buy P&G Now, Before It Sets A New All-Time High
- MarketBeat Week in Review – 03/24 – 03/28
- Top Stocks Investing in 5G Technology
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
